2019-nCoV Spike protein RBD (L452Q, F490S) (C19SD-G231MH)

2019-nCoV Spike protein RBD (L452Q, F490S) (C19SD-G231MH)

  • $100.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :   Recombinant 2019-nCoV Spike protein S1 subunit, RBD (L452Q, F490S) (319-541) was expressed in CHO cells using a C-terminal his tag. 

Species : Human

Tag :HIS tag

Expression System: CHO cells

Sequence : Full length

Genbank Number : MN908947

Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Molecular Weight : 39kDa

Gene Aliases : 2019-nCoV RBD, SARS-CoV-2 spike RBD, novel coronavirus spike RBD, nCoV spike RBD.

Scientific Background : The receptor binding domain (RBD) of SARS-CoV-2 spike glycoprotein can recognize the ACE2 receptor of the host and is an important determining factor of viral entry and neutralization (1). The Lambda variant (VUI-21JUN-01, lineage C.37) carries the mutations L452Q and F490S on its RBD and the mutations manifest resistance to antiviral immunity. In addition, the L452Q mutation further increases the viral infectivity of the virus (2). The Lambda variant was first reported in Peru in August 2020, and since then has spread to most South American countries. As more variants of the virus emerge, it is pivotal to study the transmissibility, virulence, and the possible tendency to escape antibody neutralization of the virus (3).

References :

  1. Lan J, et al: Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235
  2. Kimura I, et al: SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. bioRxiv. doi: https://doi.org/10.1101/2021.07.28.454085 
  3. Baj A, et al: Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy. Journal of Medical Virology. doi: https://doi.org/10.1002/jmv.27235

Product Sheets (By Lot #) : O3838-15